Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:30:47.229Z.
Calculation as of: 2026-10-06T13:30:47.229Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45
PEG RATIO
N/A
BlossomHill Therapeutics, Inc.
Market Cap
$583.37M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) | $583.37M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $579.66M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $595.38M | N/A |
| CorMedix Inc. (CRMD)vs › | $578.97M | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $589.38M | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $554.90M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $549.24M | N/A |
| Climb Bio, Inc. (CLYM)vs › | $636.76M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
